A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

Health experts highlight how this highly contagious disease affects vulnerable populations and share insights on prevention ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...

Clesrovimab scored on several endpoints, showing an ability to protect infants against the virus in their first RSV season.

Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the ...

Shawn Johnson shares daughter Drew Hazel, 4, and sons Jett James, 2, and Barrett 'Bear' Madison, 10 months, with her husband ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...